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Purpose: We evaluated the dose-responsiveness, efficacy, and safety of low-dose triple 
antihypertensive combination therapies in patients with mild-to-moderate hypertension.
Patients and Methods: After a 1 to 2-week placebo run-in period, 248 patients were 
randomized to the half-dose triple combination (amlodipine 2.5 mg + losartan 25 mg + 
chlorthalidone 6.25 mg), third-dose triple combination (amlodipine 1.67 mg + losartan 
16.67 mg + chlorthalidone 4.17 mg), quarter-dose triple combination (amlodipine 1.25 mg 
+ losartan 12.5 mg + chlorthalidone 3.13mg), amlodipine 10mg, amlodipine 5mg, losartan 
100mg, and placebo groups for 8 weeks. The primary outcome was the mean change in 
systolic blood pressure (SBP) from baseline to week 8.
Results: The placebo-corrected SBP reductions of the half-dose, third-dose, quarter-dose 
combination, amlodipine 10 mg, amlodipine 5 mg and losartan 100 mg treatments were 
−17.2, −19.5, −14.9, −18.5, −11.3 and −9.9 mmHg, respectively. The BP control and 
response rates were significantly higher in the half-dose, third-dose, and quarter-dose com-
bination groups than in the placebo group (all p < 0.01). Despite no intergroup differences in 
study drug-related adverse events, ankle circumference increased significantly in the amlo-
dipine group compared to those in the combination treatment groups. The quarter-dose 
combination, amlodipine 5 mg, and losartan 100 mg groups showed similar SBP reduction 
and BP response rates. The SBP reduction and BP response rate in the third-dose and half- 
dose combination groups were not significantly different from those in the amlodipine 10 mg 
group but superior to those in the losartan 100 mg group.
Conclusion: Low-dose triple combination therapies could be effective as antihypertensive 
therapies.
Trial Registration: ClinicalTrials.gov identifier NCT03897868.
Keywords: hypertension, blood pressure, combination therapy, low-dose, amlodipine, 
losartan, chlorthalidone
Introduction
Hypertension is the most prevalent risk factor of cardiovascular disease morbidity 
and mortality, and large-scale studies have shown the benefits of rapid blood 
pressure (BP) control for better cardiovascular outcomes.1,2 Although awareness 
about and treatment of hypertension have considerably improved, the control rate 
varies substantially across countries and rarely reaches the levels achieved in 
countries with high-quality regional hypertension programs.3,4 It is difficult to 
rapidly and effectively reach the target BP by using standard-dose antihyperten-
sive monotherapy with sequential upward dose titration as the initial treatment 
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strategy for mild-to-moderate hypertension because of 
individual variability in response to antihypertensive 
drugs,5 modest BP responses despite an increase in 
adverse drug reactions,6 and lengthening of the time 
required to control BP.7 Therefore, to reach the target 
BP, recent guidelines recommend using combinations of 
different classes of antihypertensive drugs as an initial 
treatment for hypertension.8,9 However, the combination 
of antihypertensive drugs at standard doses as an initial 
treatment for hypertension may be associated with an 
increase in adverse drug reactions including excessive 
BP lowering, despite providing better BP control rates.10
There is a growing interest in combination treatment 
with low-dose antihypertensive drugs. In meta- 
analyses,10,11 low-dose combinations were reported to 
show comparable or superior BP-lowering efficacy with 
fewer side effects than those associated with standard-dose 
monotherapy. The BP-lowering efficacy seemed to depend 
on the number of combined low-dose antihypertensive 
drugs. The results of these meta-analyses10,11 indicate the 
considerable promise of low-dose combinations of antihy-
pertensive drugs as first-line therapies for mild-to- 
moderate hypertension to achieve earlier BP control with 
fewer side effects. However, no studies have evaluated the 
BP-lowering efficacy and dose-responsiveness of low-dose 
triple combination therapy. Therefore, the objective of this 
study was to assess the dose-responsiveness, efficacy, and 
safety of low-dose triple combinations of antihypertensive 




This was a multicenter, randomized, double-blind, parallel- 
group, phase II study, conducted at 16 hospitals in the 
Republic of Korea. The study protocol and informed consent 
form were approved by the regulatory authority of the Korea 
Ministry of Food and Drug Safety and the institutional 
review board of each participating institution (Online 
Supplement pp 27). This study was conducted in accordance 
with Declaration of Helsinki. Figure 1 shows the study flow. 
We investigated the dose-responsiveness, efficacy, and 
safety of the following therapies in comparison with placebo 
in patients showing mild-to-moderate hypertension: half- 
dose triple combination (amlodipine 2.5 mg + losartan 
potassium 25 mg + chlorthalidone 6.25 mg; HCP1803-2.5/ 
25/6.25), third-dose triple combination (amlodipine 1.67 mg 
+ losartan potassium 16.67 mg + chlorthalidone 4.17 mg; 
HCP1803-1.67/16.67/4.17), and quarter-dose triple combi-
nation (amlodipine 1.25 mg + losartan potassium 12.5 mg + 
chlorthalidone 3.13 mg; HCP1803-1.25/12.5/3.13) thera-
pies; monotherapy with amlodipine (5 and 10 mg; 
Norvasc®, Pfizer Pharmaceutical Korea Ltd.); and mono-
therapy with losartan potassium (100 mg; Cozaar®, MSD 
Korea Ltd.). We selected combinations of amlodipine, losar-
tan potassium, and chlorthalidone because fixed standard 
doses of single-pill combination drugs have been approved 
and are already in use in Korea, with proven efficacy and 
safety in a Phase III study12 and lack of pharmacokinetic 
drug–drug interaction between component drugs in a Phase 
I study (unpublished data, NCT02387554).13 At Visit 1, 
Figure 1 Study flow.
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subjects who satisfied the inclusion/exclusion criteria parti-
cipated in a 1- to 2-week run-in period, during which they 
received placebo once daily. At the randomization visit, 
subjects who satisfied the eligibility criteria were randomly 
allocated to one of the seven treatment groups and were 
administered the assigned study drug for 8 weeks.
Study Population
Participants were eligible if they were aged ≥19 years and 
satisfied the criteria of the mean sitting systolic BP (SBP) 
of ≥140 to <180 mmHg and mean sitting diastolic BP 
(DBP) of <110 mmHg at the screening (Visit 1) and 
randomization (Visit 2) visits. The important exclusion 
criteria were as follows: a difference greater than 
20 mmHg for the mean sitting SBP or 10 mmHg for the 
mean sitting DBP between two arms; a difference of >15 
mmHg in the mean sitting SBP between Visit 1 and Visit 
2; use of an antihypertensive drug within 2 weeks of Visit 
1 or necessity of taking contraindicated medication during 
the trial period; serious cardiovascular or ischemic heart 
disease within 6 months before the trial; severe heart 
disease (NYHA class III–IV heart failure); clinically sig-
nificant renal (serum creatinine level: ≥2 mg/dL) or hepa-
tic diseases (aspartate transaminase or alanine 
transaminase level: ≥3 times the upper limit of normal); 
a history of hypersensitivity to amlodipine, losartan, 
chlorthalidone, dihydropyridines, angiotensin II receptor 
blockers, or thiazide diuretics; and women who were 
pregnant, breastfeeding, or of childbearing potential with-
out the willingness to practice adequate contraception 
throughout the study. Patients with the mean sitting SBP 
or DBP of ≥180 or ≥110 mmHg, respectively, at any visit 
after randomization, and/or with the mean sitting SBP or 
DBP of <100 or <60 mmHg, respectively, at any visit 
during the study were dropped from the study for safety. 
Other exclusion criteria and withdrawal criteria are pro-
vided in the online supplement pp 28–30. All participants 
provided written informed consent before participation in 
the study.
Randomization and Masking
Patients were randomly assigned to one of the seven 
treatment groups in a 1:1:1:1:1:1:1 ratio. Randomization 
was stratified based on the sitting SBP (<160 or ≥160 
mmHg at Visit 2). The randomization list was generated 
using the PROC PLAN procedure of SAS software. The 
randomization list contained information about the drug 
administration group to which each subject was 
allocated according to the randomization number. 
Patients were randomly assigned centrally using the 
interactive web response system to provide and manage 
the study drug.
Patients, investigators, clinical research pharmacists 
of each institution, and sponsors were masked to the 
assigned drugs until the end of the study. The combi-
nation drugs and placebo were manufactured as 
finished pharmaceutical products by Hanmi 
Pharmaceutical Co., Ltd. To maintain a double-blind 
status, the study drugs were packaged as gelatin cap-
sules (DB caps®; Capsugel, Greenwood, SC, USA) and 
the capsules were packaged to be similar in weight. All 
study drugs were prepared and packaged at 
a manufacturing facility licensed with a Certificated 
of Good Manufacturing Practice by the Korea 
Ministry of Food and Drug Safety.
Study Procedure
During the 1- to 2-week run-in period, one placebo tablet 
was administered daily to all the subjects in a single- 
blinded manner. During the 8-week treatment period, all 
subjects were instructed to take the assigned study drug 
once daily every morning for the study duration. During 
the treatment period, each subject visited the clinical trial 
institution during week 0 (Visit 2), week 4 (Visit 3), and 
week 8 (Visit 4) for the assessments of efficacy and safety.
BP was measured using an electronic sphygmoman-
ometer (HEM-7080IC, Omron, Tokyo, Japan). At each 
visit, BP was measured twice with a 2-min interval, and 
the mean value of the two measurements was used. At the 
screening visit, the index arm showing the higher mean 
SBP was determined and all subsequent BP measurements 
were conducted on the index arm. If the difference 
between two consecutively obtained readings of sitting 
SBP was >5 mmHg, the measurement was repeated. SBP 
values with a difference within 5 mmHg from two con-
secutive measurements were used to calculate the mean 
sitting SBP and DBP.
All adverse events (AEs) were assessed at every visit 
and recorded on the electronic Case Report Form.
Outcomes
The primary outcome was the change in the mean sitting 
SBP from baseline to week 8. The secondary outcomes 
were (1) change in the mean sitting SBP from baseline to 
week 4, (2) change in the mean sitting DBP from baseline 
to weeks 4 and 8, (3) BP control rate after 4 and 8 weeks 
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(percentage of subjects with sitting SBP of <140 and 
sitting DBP of <90 mmHg), (4) BP response rate after 4 
and 8 weeks (percentage of subjects with a change in 
sitting SBP of ≥20 and/or sitting DBP of ≥10 mmHg 
relative to the baseline), and (5) change in mean pulse 
pressure (mean sitting SBP – mean sitting DBP) from 
baseline to weeks 4 and 8.
Safety was assessed based on AEs; vital signs; and 
clinical laboratory test, physical examination, electrocar-
diography, and ankle edema test findings. As an assess-
ment of peripheral edema, we measured the ankle 
circumference at Visit 2 (baseline), Visit 3 (week 4), and 
Visit 4 (week 8). Briefly, the ankle circumference 5 cm 
proximal to the midpoint of the medial malleolus was 
measured using a specially designed device, to ensure 
a consistent measurement location, and tension-controlled 
measuring tape.
Statistical Analysis
Generally, data are expressed as the mean (standard devia-
tion, SD) values for continuous variables and as number 
(percentage) of patients for categorical variables. Efficacy 
data analyses were performed based on the full-analysis 
set (FAS) and additionally on the per-protocol set (PPS) 
population. The FAS included all randomized patients who 
had received the study drug at least once after randomiza-
tion and had their sitting SBP measured at least once 
during the treatment period. The PPS included all eligible 
patients who completed the 8-week regimen according to 
the clinical trial protocol without serious protocol viola-
tions among the patients in the FAS. Additionally, 
a subgroup analysis was performed in patients whose base-
line sitting SBP was lower than 160 mmHg.
For pairwise comparisons of the changes in sitting 
SBP, sitting DBP, and pulse pressure from baseline to 
weeks 4 and 8, analysis of covariance (ANCOVA) was 
performed with the baseline values and stratification vari-
ables (except for the variables related to sitting SBP) as 
covariates. Because the main purpose of this exploratory 
phase II study was to demonstrate the superiority of each 
triple combination treatment to placebo treatment in terms 
of changes in sitting SBP from baseline to week 8, multi-
ple comparison among groups was not considered. To 
compare the BP control rate and BP response rate after 4 
and 8 weeks between each treatment group, respectively, 
Pearson’s chi-square test or Fisher’s exact test was used. 
For subjects with missing values, the last-observation- 
carried-forward (LOCF) approach was applied.
Safety data were analyzed based on the safety analysis 
set population, which included patients who had taken the 
study drug at least once after randomization and had 
undergone the safety assessment at least once during the 
treatment period. AEs were presented as the number (per-
centage) of patients and events for AEs occurring after the 
randomization (treatment-emergent AEs: TEAEs). 
Moreover, TEAEs were summarized as serious AEs, 
according to severity, as AEs resulting in withdrawal, 
and study drug-related AEs. The ankle circumference 
with the greater absolute value of change from baseline 
at week 8 was used. The comparison of the changes in 
ankle circumference between the combination treatment 
(quarter-dose + third-dose + half-dose) and amlodipine 
treatment (amlodipine 5 mg + amlodipine 10 mg) groups 
was conducted based on the FAS. The LOCF method was 
applied for subjects with missing values. The Wilcoxon 
rank-sum test was used for between-group comparisons, 
and the Wilcoxon signed-rank test was used for within- 
group comparisons. For changes in laboratory parameters 
after 8 weeks relative to baseline, ANCOVA or the 
Wilcoxon rank-sum test was used for between-group 
comparison.
The effects of low-dose triple combinations on BP 
could not be predicted because there is no previous 
study. Therefore, considering the exploratory characteristic 
of phase II clinical trials, the sample size was calculated 
based on the difference in the BP-lowering effect between 
the amlodipine 5 mg and placebo groups. A sample size of 
210 patients (30 per treatment group) was calculated as 
sufficient to have 80% power to detect a difference of 
10.97 mmHg in change from the baseline sitting SBP 
between the amlodipine 5 mg and placebo treatment 
groups with a 0.05 two-sided significance level, assuming 
an SD of 12.90 mmHg and a 20% dropout rate.14–16
SAS software, version 9.4 (SAS Institute, Cary, North 
Carolina) was used for statistical analyses. This trial was 
registered with ClinicalTrials.gov, NCT03897868.
Results
Between March 2019 and January 2020, 383 patients were 
screened, and 248 patients who were eligible for the trial 
were randomized among seven groups including the pla-
cebo group (Figure 2). Six patients declined study drug 
initiation after randomization, and 238 patients were 
included in the FAS. Baseline patient characteristics such 
as mean age; sex; body mass index; and rates of current 
smoking, drinking, and diabetes were similar among the 
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seven groups (Table 1). Intergroup differences in baseline 
SBP and DBP were not significant.
The mean reduction (SD) in SBP after the 8-week 
treatment period was −18.1 (10.4) mmHg, −20.6 (17.9), 
−16.1 (13.6), −19.5 (10.7), −12.4 (13.1) and −11.1 (15.9) 
mmHg in the half-dose combination, third-dose combina-
tion, quarter-dose combination, amlodipine 10 mg, amlo-
dipine 5 mg and losartan 100 mg groups, respectively 
(Supplementary Table S1 and Figure S1). The placebo- 
corrected difference in SBP reduction (95% confidence 
interval, 95% CI) was −17.2 mmHg (−24.4 to −10.0) for 
the half-dose combination, −19.5 mmHg (−28.2 to −10.8) 
for the third-dose combination, −14.9 mmHg (−22.7 to 
−7.1) for the quarter-dose combination, −18.5 mmHg 
(−25.9 to −11.0) for the amlodipine 10 mg, −11.3 mmHg 
(−19.2 to −3.5) for the amlodipine 5 mg and −9.9 mmHg 
(−18.2 to −1.5) for the losartan 100 mg group (Figure 3A 
and Supplementary Table S1). Among the patients with 
baseline SBP of <160 mmHg (n = 178, 70% of the study 
population), there seemed to be a trend of a dose- 
dependent reduction in SBP after the 8-week treatment 
period among the half-dose, third-dose, and quarter-dose 
combination groups, although statistical significance was 
not reached (−17.8, −16.11, and −13.1 mmHg, respec-
tively, p = 0.0843) (Figure 3B and Supplementary 
Table S11).
The mean reduction in DBP (SD) from baseline at 8 
weeks in the half-dose, third-dose, and quarter-dose com-
bination groups was −8.7 (6.9), −9.3 (7.8), and −8.0 (8.5) 
mmHg, respectively. The difference in DBP (95% CI) 
reduction between the half-dose combination and placebo 
groups was −9.4 mmHg (−13.5 to −5.2), between the 
third-dose combination and placebo groups was −10.0 
mmHg (−14.3 to −5.7), and between the quarter-dose 
combination and placebo groups was −8.2 mmHg (−12.7 
to −3.6) (Supplementary Table S2 and Figure S2).
The BP control rates at week 8 in the half-dose, third- 
dose, and quarter-dose combination groups (63.9%, 
69.7%, and 57.1%, respectively) were significantly 
higher than that in the placebo group (18.2%, p = 
0.0001, p < 0.0001, and p = 0.0010, respectively) 
(Figure 4A and Supplementary Table S5). The BP 
response rates at week 8 in the half-dose, third-dose, 
and quarter-dose combination groups (58.3%, 60.6%, 
and 51.4%, respectively) were significantly higher than 
that in the placebo group (21.2%, p = 0.0017, p = 0.0011 
and p = 0.0098, respectively) (Figure 4B and supplemen 
tary Table S6). Changes in the mean SBP and DBP from 
baseline to week 4 and in pulse pressure from baseline to 
weeks 4 and 8, and BP control and response rate at week 
4 are shown in Supplementary Tables S3 and S4 and S6 
and S9 and S10 and Figure S3.
Figure 2 Patient disposition.
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In comparison with each component drugs, the quarter- 
dose combination resulted in a similar SBP reduction from 
baseline to week 8 as did amlodipine 5 mg (difference −3.8 
mmHg, 95% CI −10.1 to 2.5) and losartan 100 mg (differ-
ence −5.1 mmHg, 95% CI −11.9 to 1.6) (Supplementary 
Table S1). The BP response rate at week 8 in the quarter- 
dose combination group (51.4%) was not different from 
that in the amlodipine 5 mg and losartan 100 mg groups 
(47.1%, p = 0.7166; 32.4%, p = 0.1085, respectively) 
(Figure 4B and Supplementary Table S6). Of note, the 
SBP control rate (percentage of subjects with sitting SBP 
of <140 mmHg) and SBP response rate (percentage of 
subjects with SBP reduction of ≥20 mmHg) in the quarter- 
dose combination group at week 4 were significantly 
greater than the corresponding values in the amlodipine 
5 mg group (65.7% vs 41.2%, p = 0.0410; 42.9% vs 
17.7%, p = 0.0229, respectively) (Supplementary Tables 
S7 and S8, Figures S4 and S5). The third-dose combination 
group showed no difference in SBP reduction at week 8 
compared to that in the amlodipine 10 mg group (difference 
−1.4 mmHg, 95% CI −8.1 to 5.3). However, the SBP 
reduction was significant compared to the findings in the 
amlodipine 5 mg and losartan 100 mg group (difference 
−8.6 mmHg, 95% CI −15.9 to −1.4 and difference −10.1 














N 238 36 33 35 33 34 34 33
Age (years) 64 (11) 64 (8) 64 (11) 60 (12) 65 (10) 63 (10) 66 (12) 62 (14)
Sex
Male 166 (70%) 27(75%) 25 (76%) 23 (66%) 22 (67%) 22 (65%) 24 (71%) 23 (70%)
Female 72 (30%) 9(25%) 8 (24%) 12 (34%) 11 (33%) 12 (35%) 10 (29%) 10 (30%)
BMI (kg/m2) 25.4 (3.2) 26.8 (3.7) 25.3 (3.2) 24.9 (3.3) 24.5 (3.1) 25.3 (3.0) 25.3 (3.0) 25.5 (3.2)
Current smoker 41 (17%) 8 (22%) 9 (27%) 3 (9%) 5 (15%) 6 (18%) 4 (12%) 6 (18%)
Drinking 125 (53%) 22 (61%) 17 (52%) 19 (54%) 19 (58%) 16 (47%) 16 (47%) 16 (48%)
Diabetes 60 (25%) 12 (33%) 7 (21%) 9 (26%) 7 (21%) 8 (24%) 10 (29%) 7 (21%)
Sitting systolic blood 
pressure (mmHg)




91.6 (8.9) 92.4 (8.8) 91.3 (8.7) 94.1 (8.7) 90.68 (11.5) 92.5 (8.3) 89.3 (7.5) 90.5 (8.5)
Notes: Half-dose combination, amlodipine/losartan/chlorthalidone 2.5/25/6.25mg; Third-dose combination, amlodipine/losartan/chlorthalidone 1.67/16.67/4.17mg; Quarter- 
dose combination, amlodipine/losartan/chlorthalidone 1.25/12.5/3.13mg; Data are mean (SD) or number of patients (%).
Figure 3 Change of sitting systolic blood pressure from baseline at week 8. (A) Full analysis set, (B) patients with sitting systolic blood pressure < 160 mmHg at baseline.
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mmHg, 95% CI −17.6 to −2.5) (Supplementary Table S1). 
The half-dose combination group showed no difference in 
SBP reduction at week 8 compared to that in the amlodipine 
10 mg group (difference 1.5 mmHg, 95% CI −3.6 to 6.6), 
an insignificant but marginal difference compared to that in 
the amlodipine 5 mg group (difference −5.7 mmHg, 95% 
CI −11.4 to 0.0), and a significant difference compared to 
that in the losartan 100 mg group (difference −6.8 mmHg, 
95% CI −13.2 to −0.5) (Supplementary Table S1). The BP 
response rates at week 8 in the half-dose combination 
(58.3%) and third-dose combination (60.6%) groups were 
significantly higher than that in the losartan 100 mg group 
(32.4%, p = 0.0292 and 0.0204, respectively), but not 
different from that in the amlodipine 10 mg group (63.6% 
and 0.7997, respectively, p = 0.6521) (Figure 4B and sup 
plementary Table S6).
Among the combination groups, the half-dose and 
third-dose combination groups showed greater SBP and 
DBP reduction and higher control and response rates 
compared to those in the quarter-dose combination 
group. However, the differences were not significant 
(Supplementary Tables S1 and S2 and S5 and S6).
Intergroup differences in study drug-related AEs were 
not significant (Table 2 and Supplementary Table S13). 
One participant (2.8%) in the half-dose combination group 
reported both dizziness and headache, which were judged 
to be related or possibly related to the study treatment. 
Moreover, one participant (2.9%) in the amlodipine 5 mg 
group reported ankle edema during the 8-week treatment 
period (Table 2). Ankle circumference significantly 
increased from baseline to week 8 in the amlodipine treat-
ment group but did not change in the combination treat-
ment groups. The difference in ankle circumference 
changes between the combination treatment and amlodi-
pine groups was significant (−0.76 mm versus 2.48 mm, 
difference −3.23 mm, 95% CI −5.53 to −0.94) (Figure 5 
and Supplementary Table S12). Changes in serum creati-
nine and sodium levels after the 8-week treatment period 
in the half-dose, third-dose, and quarter-dose combination 
groups were not different from those in the placebo group 
Figure 4 Control and response rate of blood pressure at week 8. (A) control rate, (B) response rate.














n 36 33 35 33 34 35 35
Ankle edema - - - - 1 (2.9) - -
Dizziness 1 (2.8) - - - - - -
Headache 1 (2.8) - - - - - 1 (2.9)
Pruritus - - - - - 1 (2.9) -
Skin lesion - - - - 1 (2.9) - -
Notes: Half-dose combination, amlodipine/losartan/chlorthalidone 2.5/25/6.25mg; Third-dose combination, amlodipine/losartan/chlorthalidone 1.67/16.67/4.17mg; Quarter- 
dose combination: amlodipine/losartan/chlorthalidone 1.25/12.5/3.13mg; Data are number of events (%).
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(Table 3). However, the mean change (SD) in serum blood 
urea nitrogen (BUN) level in the half-dose combination 
group was 1.94 (3.43) mg/dL and was significantly differ-
ent from that in the placebo group (−0.37 (3.42) mg/dL, 
difference 2.31 mg/dL, 95% CI 0.57 to 4.06). The mean 
change (SD) in serum potassium level in the half-dose 
combination group was −0.22 (0.35) mmol/L and was 
significantly different from that in the placebo group 
(−0.03 (0.28) mmol/L, difference −0.15 mmol/L, 95% CI 
−0.28 to −0.02) (Table 3). Changes in other laboratory 
parameters and summary of serious adverse events are 
shown in Supplementary Tables S14 and S15, respectively.
Discussion
In the present study, we showed that low-dose triple com-
bination therapies provided effective BP lowering efficacy 
in patients with mild to moderate hypertension. The pla-
cebo-corrected BP lowering was 17.2/9.4, 19.5/10.0, and 
14.9/8.2 mmHg for the half-dose triple combination, third- 
dose triple combination, and quarter-dose triple combina-
tion therapies, respectively. The BP control and response 
rates in the quarter-dose, third-dose, and half-dose triple 
combination groups were significantly higher than the 
corresponding rate in the placebo group. After the 
Figure 5 Changes in ankle circumference from baseline at week 8.














n 36 33 35 33 34 35 35
Creatinine, mg/dL
Mean changes from baseline 
at week 8
0.00 (0.10) 0.03 (0.08) −0.00 (0.07) −0.03 (0.11) −0.01 (0.07) 0.04 (0.10) −0.01 
(0.08)
Difference of changes 
compared to placebo






p value 0.8078† 0.1065† 0.8059† 0.2897† 0.8088† 0.1185†
BUN, mg/dL
Mean changes from baseline 
at week 8
1.94 (3.43) 1.61 (3.86) 0.52 (3.91) −0.63 (2.95) −0.48 (4.10) 0.06 (3.40) −0.37 
(3.42)
Difference of changes 
compared to placebo






p value 0.0225† 0.0618† 0.5883* 0.8242† 0.8426* 0.7540*
Serum sodium, mmol/L
Mean changes from baseline 
at week 8
−0.58 (1.50) −0.91 (2.16) −0.61 (2.01) −0.41 (2.17) 0.58 (1.84) −0.06 (1.88) −0.15 
(1.49)










p value 0.1035* 01163* 0.3731† 0.2710* 0.2108* 0.8502*
Serum potassium, mmol/L
Mean changes from baseline 
at week 8
−0.22 (0.35) −0.12 (0.36) −0.13 (0.28) −0.14 (0.40) −0.14 (0.32) 0.02 (0.39) −0.03 
(0.28)










p value 0.0245* 0.4027* 0.4030† 0.1758* 0.1904* 0.3803†
Notes: Half-dose combination, amlodipine/losartan/chlorthalidone 2.5/25/6.25mg; Third-dose combination, amlodipine/losartan/chlorthalidone 1.67/16.67/4.17mg; Quarter- 
dose combination, amlodipine/losartan/chlorthalidone 1.25/12.5/3.13mg; p value, *ANCOVA and †Wilcoxon rank sum test, compared to placebo group.
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8-week treatment period, ankle circumference did not 
change in the combination therapy groups but increased 
in the amlodipine monotherapy group. Furthermore, there 
was a significant difference in changes in ankle circumfer-
ence between the combination therapy and amlodipine 
groups. Along with changes in ankle circumference, one 
case of ankle edema was reported in the amlodipine 5 mg 
group.
In comparison with each component drug, a further 
significant reduction of 8.6 mmHg compared to that 
achieved with amlodipine 5 mg monotherapy was 
achieved with third-dose triple combination therapy. The 
point estimates of 3.8 mmHg with the quarter-dose triple 
combination therapy and 5.7 mmHg with the half-dose 
triple combination therapy from amlodipine 5 mg mono-
therapy were not significant; however, differences of this 
extent would be regarded as clinically relevant. These 
results suggest possibility of a new therapeutic option for 
a stepped-care approach involving initial treatment with 
a quarter-dose triple combination therapy as the first-line 
treatment and up-titration to third-dose or half-dose triple 
combination therapy for the management of mild-to- 
moderate hypertension, similar to the stepped-care therapy 
starting from amlodipine 5 mg and up-titrating to amlodi-
pine 10 mg.
Combination of low-dose antihypertensive drugs has 
been suggested as an option for hypertension treatment 
because of increased efficacy and reduced adverse 
effects.10 In a meta-analysis, the BP-lowering efficacy of 
half-standard-dose triple combination therapy was pre-
dicted to be 20/11 mmHg.10 Similar to the predicted effi-
cacy, the placebo-corrected BP lowering of the half-dose 
triple combination was 17.2/9.4 mmHg in our study and 
comparable to that of amlodipine 10 mg. Only a few 
studies have evaluated the BP-lowering efficacy of low- 
dose combinations of three or four antihypertensive drugs. 
In a double-blind placebo-controlled crossover trial of 
a Polypill containing half the standard doses of three 
antihypertensive drugs and simvastatin, the placebo- 
corrected BP-lowering effect was 18/10 mmHg and simi-
lar to the effect predicted by the meta-analysis.17 The BP- 
lowering efficacy of a quarter-dose quadruple combination 
was higher than that of the standard dose of each compo-
nent drug.18 The placebo-corrected BP-lowering efficacy 
of the quarter-dose quadruple combination was 22/13 
mmHg in a randomized, placebo-controlled, crossover 
trial.19 Based on the results of previous studies,18,19 the 
BP-lowering efficacy of the quarter-dose triple 
combination therapy seems to be between that of the 
quarter-dose quadruple combination and quarter-dose 
dual combination therapies. The initiation of low-dose 
dual combination therapy was evaluated, and it provided 
the benefits of better and earlier BP control than that 
afforded by the conventional stepped-care up-titration 
approach for monotherapies.7,20 In an open-label trial, 
low-dose triple combination treatment showed a higher 
rate of target BP goal achievement than that achieved 
with the usual care approach21 and was analyzed to be 
cost-effective.22 In terms of side effects, the reductions in 
sodium and potassium levels were greater in the low-dose 
combination treatment using chlorthalidone 12.5 mg than 
those associated with the usual care treatment.21 In the 
present study, the half-dose triple combination therapy 
significantly lowered the serum potassium level compared 
to that associated with the placebo treatment, but the 
quarter- and third-dose triple combination therapies did 
not. However, the difference in changes between the half- 
dose triple combination and placebo groups was relatively 
small, and the mean serum potassium level lowered from 
4.43 to 4.21 mmol/L, suggesting a low probability of 
clinical significance. The changes in serum creatinine and 
sodium levels were similar to those associated with the 
placebo treatment.
The strength of our study is that this is the first study, 
to our knowledge, to evaluate the dose-responsiveness of 
low-dose triple antihypertensive drug combinations (quar-
ter-dose, third-dose, and half-dose) therapies in compari-
son to that of placebo. Although our study was not 
designed to compare the efficacy of low-dose triple com-
bination treatments with each component drug therapy and 
further trials are needed, the comparable efficacy of the 
quarter-dose combination therapy and amlodipine 5 mg 
therapy and that of the third-dose and half-dose combina-
tion therapies with amlodipine 10 mg suggests the possi-
bility of a new therapeutic option for stepped-care 
treatment involving initial treatment with the quarter- 
dose triple combination drug therapy and up-titration to 
the third-dose or half-dose triple combination drug therapy 
for the management of mild-to-moderate hypertension. 
The better SBP control and response rate with the quarter- 
dose triple combination therapy compared to those with 
the amlodipine 5 mg monotherapy at week 4 also suggests 
the likelihood of rapid achievement of the target BP goal 
by initiating treatment with quarter-dose triple combina-
tion therapy in patients with mild-to-moderate 
hypertension.
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Because of the small sample size and short study 
duration, in our study, we measured the ankle circumfer-
ence to assess the development of peripheral edema. The 
low-dose triple combination therapies were not associated 
with an increase in ankle circumference, but amlodipine 
treatment was associated with an increase in ankle circum-
ference. However, it is unclear whether an increase in 
ankle circumference in our study is clinically relevant 
and whether it would progress to apparent peripheral 
edema after long-term exposure.8 The introduction of low- 
dose triple combination drug therapies as first-line thera-
pies in the management of hypertension is expected to 
reduce treatment inertia among patients and physicians 
because these therapies could help achieve the target BP 
more rapidly with fewer side effects than those associated 
with the conventional stepped-care approach starting with 
a standard-dose monotherapy.
The limitations of our study are the short study 
duration and small sample size. An 8-week treatment 
period is not enough to evaluate the sustained BP- 
lowering effect and AEs that occur after long-term 
treatment. This study was an exploratory phase II 
study and primarily designed to determine the optimal 
low-dose triple combinations by evaluating superiority 
of BP lowering efficacy compared to placebo treat-
ment. Therefore, whether low-dose triple combination 
therapies had efficacy and tolerability comparable to 
that of each component drug monotherapy could not 
be confirmed. Whether the initiation of low-dose com-
bination therapies may provide better protection against 
cardiovascular diseases through early BP control 
should be evaluated in long-term follow-up studies 
with large study populations. In addition, pharmacoki-
netic and pharmacodynamics studies of low-dose com-
bination drugs is needed because they may provide an 
insight into the mechanism of hypotensive effect of 
low-dose combination drugs.
Conclusion
In conclusion, the placebo-corrected BP-lowering effect of 
low-dose triple combination therapies demonstrated in our 
study indicates that these therapies could be effective as 
antihypertensive therapies. The favorable effect on ankle 
edema could be an additional advantage of low-dose triple 
combination drug therapies when compared to conven-
tional amlodipine monotherapies for hypertension 
management.
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